CA
NZ
UK
AU
IND
US
● Kisqali sales rose 43% in constant currencies to US$1.7bn.
● Aardvark terminated the Phase 3 HERO trial and open-label extension in June 2026.
● Skyrizi sales reached US$5.505 billion, while Humira fell 35.9% to US$756 million.
● No serious or severe adverse events or discontinuations due to adverse events were reported.
No company release dated October 14, 2026 explains the advance, and the print is thin. A volume of 500 shares at CAD 2.80 equals roughly CAD 1,400 of value traded, so one or two small orders can move a quote on the Canadian Securities …
DRI Healthcare Trust, a pharmaceutical royalty company, saw its US-dollar units fall 9.15% to USD 11.62 on October 14 on only 519 units, 1.38 times a very small average. The latest company news is the September 21 announcement of a USD 316 million purchase …
The October 13, 2026 release said Liquidia will not appeal the September 30 ruling and has filed a supplement to remove the pulmonary hypertension associated with interstitial lung disease indication from the Yutrepia label. The settlement resolves six lawsuits, and dismissals with prejudice follow …
Capricor Therapeutics (NASDAQ:CAPR) had no company-specific news on October 13, 2026, and volume was well below average. The share price reflects the regulatory path for deramiocel, a cell therapy for Duchenne muscular dystrophy. On August 24, 2026 the company disclosed that the FDA moved …
No company announcement dated October 14, 2026 was found, so the 3.45% gain looks like a continuation of sentiment built by the August 5 results. Eli Lilly reported revenue growth of 48% to USD 22.97 billion, led by the incretin franchise. Mounjaro, a tirzepatide …
No company announcement dated October 14, 2026 was found, so the 3.85% gain follows earlier developments. Revolution Medicines reported research and development expense of USD 394.9 million, up from USD 224.1 million, and general and administrative expense of USD 110.2 million, up from USD …
Please wait processing your request...